Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...

Unlike current treatments on the market for hereditary angioedema, navenibart requires dosing only every 3-6 months.

USA: Switching to garadacimab may provide a safe and effective option for preventing hereditary angioedema (HAE) attacks, according to interim findings from an ongoing Phase 4 clinical study. Patients ...

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...

BioCryst Pharmaceuticals (NASDAQ:BCRX) executives highlighted the company’s transition to profitability, continued growth of ...

BASF has filed applications in Durham County to build an approximately 157,000-square-foot research and development facility at its campus on T.W. Alexander Drive, according to the Triangle Business ...

Slate Medicines, a new Raleigh biotechnology company developing treatments for migraine and headache disorders, has announced ...

Yesterday, the agency released new guidelines concerning plausible mechanisms of action for gene editing and RNA-based therapies. This updated framework permits the use of "basket" studies, enabling ...

Intellia Therapeutics has received full clearance from the U.S. Food and Drug Administration (FDA) to resume its pivotal Phase 3 clinical trial, known as MAGNIT ...

Kylie is the Global Live Pages Editor, leading a team providing real-time multimedia coverage of the biggest breaking stories worldwide. She previously worked on the UK Breaking News team, and spent ...